723 related articles for article (PubMed ID: 34691042)
21. 'Off-the-shelf' allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies.
Sinha D; Srihari S; Beckett K; Le Texier L; Solomon M; Panikkar A; Ambalathingal GR; Lekieffre L; Crooks P; Rehan S; Neller MA; Smith C; Khanna R
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589524
[TBL] [Abstract][Full Text] [Related]
22. Identification of multiple potent neutralizing and non-neutralizing antibodies against Epstein-Barr virus gp350 protein with potential for clinical application and as reagents for mapping immunodominant epitopes.
Mutsvunguma LZ; Rodriguez E; Escalante GM; Muniraju M; Williams JC; Warden C; Qin H; Wang J; Wu X; Barasa A; Mulama DH; Mwangi W; Ogembo JG
Virology; 2019 Oct; 536():1-15. PubMed ID: 31377598
[TBL] [Abstract][Full Text] [Related]
23. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
[TBL] [Abstract][Full Text] [Related]
24. GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies.
Zhang X; Wang T; Zhu X; Lu Y; Li M; Huang Z; Han D; Zhang L; Wu Y; Li L; Klawonn F; Stripecke R
Front Immunol; 2023; 14():1103695. PubMed ID: 36817460
[TBL] [Abstract][Full Text] [Related]
25. A Pentavalent Epstein-Barr Virus-Like Particle Vaccine Elicits High Titers of Neutralizing Antibodies against Epstein-Barr Virus Infection in Immunized Rabbits.
Escalante GM; Foley J; Mutsvunguma LZ; Rodriguez E; Mulama DH; Muniraju M; Ye P; Barasa AK; Ogembo JG
Vaccines (Basel); 2020 Apr; 8(2):. PubMed ID: 32268575
[TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
[TBL] [Abstract][Full Text] [Related]
27. A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.
Taylor GS; Jia H; Harrington K; Lee LW; Turner J; Ladell K; Price DA; Tanday M; Matthews J; Roberts C; Edwards C; McGuigan L; Hartley A; Wilson S; Hui EP; Chan AT; Rickinson AB; Steven NM
Clin Cancer Res; 2014 Oct; 20(19):5009-22. PubMed ID: 25124688
[TBL] [Abstract][Full Text] [Related]
28. Identification of GLA/SE as an effective adjuvant for the induction of robust humoral and cell-mediated immune responses to EBV-gp350 in mice and rabbits.
Heeke DS; Lin R; Rao E; Woo JC; McCarthy MP; Marshall JD
Vaccine; 2016 May; 34(23):2562-9. PubMed ID: 27085175
[TBL] [Abstract][Full Text] [Related]
29. DNA-mediated immunization of glycoprotein 350 of Epstein-Barr virus induces the effective humoral and cellular immune responses against the antigen.
Jung S; Chung YK; Chang SH; Kim J; Kim HR; Jang HS; Lee JC; Chung GH; Jang YS
Mol Cells; 2001 Aug; 12(1):41-9. PubMed ID: 11561729
[TBL] [Abstract][Full Text] [Related]
30. The Development of Prophylactic and Therapeutic EBV Vaccines.
Smith C; Khanna R
Curr Top Microbiol Immunol; 2015; 391():455-73. PubMed ID: 26428385
[TBL] [Abstract][Full Text] [Related]
31. EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design.
Khanna R; Sherritt M; Burrows SR
J Immunol; 1999 Mar; 162(5):3063-9. PubMed ID: 10072559
[TBL] [Abstract][Full Text] [Related]
32. Genome-Wide Analysis of Epstein-Barr Virus Isolated from Extranodal NK/T-Cell Lymphoma, Nasal Type.
Lin N; Ku W; Song Y; Zhu J; Lu Z
Oncologist; 2019 Sep; 24(9):e905-e913. PubMed ID: 30940744
[TBL] [Abstract][Full Text] [Related]
33. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
Ressing ME; Horst D; Griffin BD; Tellam J; Zuo J; Khanna R; Rowe M; Wiertz EJ
Semin Cancer Biol; 2008 Dec; 18(6):397-408. PubMed ID: 18977445
[TBL] [Abstract][Full Text] [Related]
34. Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities.
Dasari V; Bhatt KH; Smith C; Khanna R
Expert Rev Vaccines; 2017 Apr; 16(4):377-390. PubMed ID: 28276306
[TBL] [Abstract][Full Text] [Related]
35. Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective.
Escalante GM; Mutsvunguma LZ; Muniraju M; Rodriguez E; Ogembo JG
Front Immunol; 2022; 13():867918. PubMed ID: 35493498
[TBL] [Abstract][Full Text] [Related]
36. Computer-Aided Design of an Epitope-Based Vaccine against Epstein-Barr Virus.
Alonso-Padilla J; Lafuente EM; Reche PA
J Immunol Res; 2017; 2017():9363750. PubMed ID: 29119120
[TBL] [Abstract][Full Text] [Related]
37. Vaccination against the Epstein-Barr virus.
Rühl J; Leung CS; Münz C
Cell Mol Life Sci; 2020 Nov; 77(21):4315-4324. PubMed ID: 32367191
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity of a multiepitope plasmid DNA encoding T and B lymphocyte epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a vaccine in mice.
Li W; Chen Q; Lin Q; Lv Y; Feng J; Liu J; Xu W; Chen S; Zhu X; Zhang L
Protein Pept Lett; 2013 Oct; 20(10):1136-43. PubMed ID: 23688153
[TBL] [Abstract][Full Text] [Related]
39. Recombinant Epstein-Barr virus glycoprotein 350 as a serological antigen.
Persson Berg L; Thomsson E; Hasi G; Bäckström M; Bergström T
J Virol Methods; 2020 Oct; 284():113927. PubMed ID: 32650039
[TBL] [Abstract][Full Text] [Related]
40. Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge.
Malhi H; Homad LJ; Wan YH; Poudel B; Fiala B; Borst AJ; Wang JY; Walkey C; Price J; Wall A; Singh S; Moodie Z; Carter L; Handa S; Correnti CE; Stoddard BL; Veesler D; Pancera M; Olson J; King NP; McGuire AT
Cell Rep Med; 2022 Jun; 3(6):100658. PubMed ID: 35705092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
